bgc experimental drug developed target ovarian folate receptor alpha mediated thymidylate synthase originally developed btg institute cancer research uk subsequently licensed onyx pharmaceuticals clinical development designed selectively target tumour tissues certain kinds poorly absorbed cells actively transported folate receptor alpha frÎ± usually expressed low levels apical membrane specialised tissues expressed much higher levels subtypes ovarian cancer causes drug accumulate selectively tumour tissues healthy tissues exposed much lower received press coverage following successful completion phase clinical antineoplastic immunomodulatory drug article stub help wikipedia expanding